Review
Novel treatments and future perspectives: outcomes of intrathecal drug delivery
Affiliations
- PMID: 20040323
Item in Clipboard
Review
Novel treatments and future perspectives: outcomes of intrathecal drug delivery
Int J Clin Pharmacol Ther.
2009.
Abstract
Intrathecal enzyme replacement therapy (ERT) holds promise as a treatment for the central nervous system manifestations of lysosomal storage diseases. Treatment via the cerebrospinal fluid represents a potential method of delivering recombinant enzyme across the blood-brain barrier. Experiments in animal models of mucopolysaccharidosis (MPS) Type I, MPS II and MPS IIIA have shown that ERT delivered via the intrathecal route distributes throughout the central nervous system and penetrates brain tissue, where it promotes clearance of lysosomal storage material. Studies are underway to investigate the safety and efficacy of intrathecal ERT in patients with MPS I.
Similar articles
-
Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases.Int J Clin Pharmacol Ther. 2009;47 Suppl 1:S118-23. doi: 10.5414/cpp47118. Int J Clin Pharmacol Ther. 2009. PMID: 20040322 Review.
-
Enzyme replacement therapy for lysosomal storage diseases.Curr Opin Pediatr. 2011 Dec;23(6):588-93. doi: 10.1097/MOP.0b013e32834c20d9. Curr Opin Pediatr. 2011. PMID: 21946346 Review.
-
Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.Mol Genet Metab. 2004 Sep-Oct;83(1-2):163-74. doi: 10.1016/j.ymgme.2004.07.003. Mol Genet Metab. 2004. PMID: 15464431
-
Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice.Mol Genet Metab. 2015 May;115(1):33-40. doi: 10.1016/j.ymgme.2015.03.002. Epub 2015 Mar 12. Mol Genet Metab. 2015. PMID: 25795516
-
Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA.J Neurochem. 2016 May;137(3):409-22. doi: 10.1111/jnc.13533. Epub 2016 Feb 24. J Neurochem. 2016. PMID: 26762778
Cited by
-
Large-volume intrathecal enzyme delivery increases survival of a mouse model of late infantile neuronal ceroid lipofuscinosis.Mol Ther. 2011 Oct;19(10):1842-8. doi: 10.1038/mt.2011.130. Epub 2011 Jul 5. Mol Ther. 2011. PMID: 21730969 Free PMC article.
-
Glutathione PEGylated liposomes: pharmacokinetics and delivery of cargo across the blood-brain barrier in rats.J Drug Target. 2014 Jun;22(5):460-7. doi: 10.3109/1061186X.2014.888070. Epub 2014 Feb 14. J Drug Target. 2014. PMID: 24524555 Free PMC article.
-
Glycan-based biomarkers for mucopolysaccharidoses.Mol Genet Metab. 2014 Feb;111(2):73-83. doi: 10.1016/j.ymgme.2013.07.016. Epub 2013 Jul 29. Mol Genet Metab. 2014. PMID: 23958290 Free PMC article. Review.
-
Effective intravenous therapy for neurodegenerative disease with a therapeutic enzyme and a peptide that mediates delivery to the brain.Mol Ther. 2014 Mar;22(3):547-553. doi: 10.1038/mt.2013.267. Epub 2013 Dec 26. Mol Ther. 2014. PMID: 24394185 Free PMC article.
-
Levels of glycosaminoglycans in the cerebrospinal fluid of healthy young adults, surrogate-normal children, and Hunter syndrome patients with and without cognitive impairment.Mol Genet Metab Rep. 2015 Nov 9;5:103-106. doi: 10.1016/j.ymgmr.2015.11.001. eCollection 2015 Dec. Mol Genet Metab Rep. 2015. PMID: 28649553 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical